Sunny Pharmtech signs sales contract with Company S, aiming for a $2.4 billion opportunity in Pulmonary Fibrosis drugs

Sunny Pharmtech's pulmonary fibrosis drug NTN has signed a sales contract with Company S for the US market. In the future, Sunny Pharmtech will be responsible for production, while Company S will handle promotion and sales after the drug's market launch. Company S will also assist in planning related licensing matters, becoming Sunny Pharmtech's strategic partner in the US market, targeting the lucrative $2.4 billion market opportunity for pulmonary fibrosis drugs.